HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consumer Business Reliable And Right At Home At GlaxoSmithKline

This article was originally published in The Pink Sheet

Executive Summary

CEO Walmsley's familiarity with Glaxo's consumer health business was clear in her response to analysts' questions about the firm's future as a three-unit operation. The business marketing brands including Flonase and Excedrin is a more reliable revenue driver than the pharma business, she said.

You may also be interested in...

From Witty To Walmsley – The Priorities For GSK's New CEO

It's Emma Walmsley's first week at the helm of GlaxoSmithKline. What can we expect in terms of her priorities?

Glaxo’s Parodontax Brings Bleeding Gums Claim To US Toothpaste Battle

Parodontax contains the same OTC oral care monograph ingredient, stannous fluoride, as numerous toothpastes labeled for use on sensitive teeth, but those products don’t include the indication of helping stop bleeding gums.

GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition

GlaxoSmithKline Flonase Sensimist Allergy Relief could help fend off private label competition in the intranasal corticosteroid category, the firm says. Despite a 19% drop in sales of the original Flonase OTC in the fourth quarter, US consumer health care sales grew 5% to $2.2bn on a reported basis in 2016.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts